Strikingly, hydroxychloroquine, which improves the prevention and treatment of Q fever endocarditis,[29,30] directly reduces the binding of antiphospholipid antibodies to phospholipid bilayers,[31] prevents thrombogenic properties of antiphospholipid antibodies,[32–35] and lowers the odds of having persistently positive antiphospholipid …
Strikingly, hydroxychloroquine, which improves the prevention and treatment of Q fever endocarditis,[29,30] directly reduces the binding of antiphospholipid antibodies to phospholipid bilayers,[31] prevents thrombogenic properties of antiphospholipid antibodies,[32–35] and lowers the odds of having persistently positive antiphospholipid antibodies or lupus anticoagulant.[36,37] Consequently, adding hydroxychloroquine to doxycycline in acute Q fever patients with elevated IgG aCL levels could be useful in preventing antiphospholipid-associated complications, including thrombosis, and should be tested in future studies
Strikingly, hydroxychloroquine, which improves the prevention and treatment of Q fever endocarditis,[29,30] directly reduces the binding of antiphospholipid antibodies to phospholipid bilayers,[31] prevents thrombogenic properties of antiphospholipid antibodies,[32–35] and lowers the odds of having persistently positive antiphospholipid antibodies or lupus anticoagulant.[36,37] Consequently, adding hydroxychloroquine to doxycycline in acute Q fever patients with elevated IgG aCL levels could be useful in preventing antiphospholipid-associated complications, including thrombosis, and should be tested in future studies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521934/